About this Journal Submit a Manuscript Table of Contents
Journal of Amino Acids
Volume 2012 (2012), Article ID 206520, 8 pages
http://dx.doi.org/10.1155/2012/206520
Review Article

Environmental Factors Preceding A 40 Monomer to Oligomers and the Detection of Oligomers in Alzheimer's Disease Patient Serum

Department of Medical Pharmacology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan

Received 11 August 2011; Revised 20 October 2011; Accepted 27 October 2011

Academic Editor: Jianning Wei

Copyright © 2012 Yoichi Matsunaga and Midori Suenaga. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We present here environmental factors including pH shifts, temperature, and metal ions surrounding Aβ40 monomer to precede the oligomers. We also suggest a new idea to detect Aβ40 oligomers with anti-Aβ40 monoclonal antibody using enzyme-linked immunosorbent assay. This method involves the different sensitivity of the thermal shifts between Aβ40 monomer and the oligomers. The idea is useful for the diagnostics of Alzheimer's disease to detect Aβ40 oligomers in the serum from the patients.

1. Introduction

Alzheimer’s disease (AD) is the most common of senile dementia and characterized by memory loss, deterioration of cognitive and behavioral processes and social life, and these symptoms showed no relief through the life. The major pathological hallmark of AD is the accumulated Aβ plaques in the extracellular liquid [1] and neurofibrillary tangles in the intracellular accumulation of hyperphosphorylated and misfolded tau protein [24]. Among the brain lesions that are affected in AD and contain the highest number of senile plaques are the amygdala [5] and hippocampus [6]. The amygdala is involved in modulation of behavior, emotion, and memory due to its vast afferent and efferent projections. It has been reported that although lesions of amygdala alone do not appear to impair spatial learning, they potentiate hippocampus lesion-induced disruption of spatial learning [7]. The Aβ plaques are mainly composed of β-structured fibrils made up to β-amyloid protein 40/42 amino acid residues long (Aβ40/42), and they are processed from amyloid precursor protein (APP) in neurons and secreted into the interstitial fluid space (IFS) of the brain in the soluble form [8] and cerebrospinal fluid (CSF) that help to clear Aβ from IFS to the bloodstream [9, 10].

Some of misfolding mechanisms of Aβ to induce aggregation appear in AD brain. Because the aggregated Aβ is observed as extracellular structure, the concentration of Aβ in the ISF [15] and the environmental factors surrounding the protein may affect the process. Detection of the most toxic Aβ species to synapse and neuron [16] present during Aβ aggregation is a critical aspect in AD diagnostics. The molten-globule state of the protein that is a misfolding intermediate, Aβ oligomers before Aβ plaque formation is responsible for neuronal damages [17].

One possible model of direct Aβ cytotoxicity involves the cytopathic effect of amyloid fibrils, which are rich in β-sheets and thereby interact with cell surface receptors and result in aberrant activation of signal transduction pathways. This model in consistent with the observation of hyperphosphorylated focal adhesion kinase [18] and microtubule-associated tau protein [19]. Persistent binding and activation of cell surface receptors by amyloid fibrils may induce neuronal apoptosis. An alternative possibility of Aβs cytotoxicity is the direct damages to the cell surface membrane to form pores and induce calcium influx by hydrolytic activity of Aβ40 oligomers [20]. Recent study reports calcium ions stimulate the formation of Aβ40 oligomers that causally implicated in neuronal toxicity of AD [21].

Many candidates of AD biomarker in blood, plasma, serum, and CSF are reported. The CSF levels of Aβ42, tau and phosphorylated tau are potential biomarkers of AD [22], and plasma measures of Aβ are of limited diagnostic value but may provide important information as a measure of treatment response [23].

Many monoclonal antibodies (moAbs) to recognize Aβ40 monomer are reported, and their epitopes are determined; however, there is no specific moAb for Aβ40 oligomers. The conformational changes of Aβ40 monomer to oligomers are induced in response to physiological environments surrounding Aβ40, and some of Aβ40 sequences are responsible to the changes. We used the moAb to react with the responsible sequence to the changes.

The Aβ40 monomer is flexible and have high free energy before exposure to environmental changes, and the moAb shows high level of signals; however, after the exposure, its flexibility is constricted and free energy became low. In the steps, some epitopes of the moAb are hidden inside the oligomers and the moAb could not bind to the epitopes, which resulted in the low level of signals. The remarkable fall down of reactivity of moAb towards Aβ40 monomer is useful to distinguish from Aβ40 oligomers, because the reactivity towards Aβ40 oligomers show no changes before and after the exposure. We applied the idea to determine Aβ40 forms in Alzheimer’s disease patients serum.

2. Environmental Factors Surrounding Aβ40

Aβs on the neuronal cell are exposed to various intracellular, and extracellular environmental factors in brain. Aβs are exposed to acidic pH in lysosome and extracellular factors surrounding Aβs involve temperature, metal ions, vibration, sounds, gravity, pressure, free radicals, lipid, concentration, and chemical chaperones [24]. These factors might be responsible to induce soluble Aβ monomers to molten-globule states of oligomers which are a component of neurodegenerative process and toxic to neuronal cells (Figure 1).

206520.fig.001
Figure 1: Environmental factors surrounding Aβ40 to precede Aβ40 oligomers. Aβs are exposed to the variety of environmental factors that affect the conformational changes. These factors involve pH shift, temperature, metal ions, sounds, gravity, atmospheric pressure, and vibration. These factors might be responsible to induce soluble Aβ monomer into oligomers which is a component of neurodegenerative process.
2.1. pH Shifts

The native conformation of Aβ in AD and PrP in Scrapie is modulated by pH shift surrounding the protein, resulting in a “molten globule” state that is less ordered than native protein and is a folding intermediate to precede amyloid protein, however, still preserve the mean overall feature of the native protein [25].

In Aβ40, a critical pH to induce the conformational transition is at around pH 5, which is a mimicking of a lysozomal pH [11]. The responsible sequences to the pH shift was Aβ 9-14:GYEVHH and 17–21:LVFFA, and the Glu at position 11 is most responsible to the acidic pH shift and induce soluble Aβ40 to insoluble form [26] (Figure 2).

206520.fig.002
Figure 2: Reactivity patterns of antibodies differ after pH-modification of the Aβ40 peptide [11]. The pH-modified Aβ40 peptides (4 μg/mL) at various pH values were tested for monoclonal antibody (e.g., anti-1–7 (fuchsia diamond), anti-5–10 (green square), 6F/3D (yellow circle), and 4G8 (red triangle)) and anti-1–42 (blue circle) which is a polyclonal antibody, binding at a concentration of 1 μg/mL on the standard ELISA system. Absorbance was measured at 405 nm. Results are expressed as means ± SEM ( ). The anti-1–7 and anti-5–10 antibodies showed very similar reactivity towards Aβ40 incubated at various pH values, the reactivity remaining constant over the entire pH range. In constant, the 6F/3D antibody showed decreasing reactivity as the pH was lowered from pH 8.0 to 4.6, followed by a dramatic increase as the pH was lowered from pH 4.6 to 3.0. Interestingly, reactivity of the 4G8 antibody showed a profile similar to that shown by antibody 6F/3D, with the lowest signal at pH 4.6.

Scrapie is a disease of protein misfolding of cellular prion protein ( ), in which the largely α-helical and is converted to pathological isoform of scrapie PrP( ), that is rich in β-sheet [27, 28]. is formed in caveolae and subsequently accumulated in endosomes and secondary lysosomes where the pH falls down to around pH 4-5 [29]. A proteolytically truncated form of corresponding to PrP(90–231) retains infectivity and form amyloid fibrils [30], and truncated (PrP90–231) with the same amino acid sequence can be converted to in both cultured cells and transgenic mouse [31].

The pH dependence of PrP(90–231) was tested, and the moAbs which recognize amino acids sequence of 94–105(GTHNQWNKPSKP), 107–112(TNMKHM), and 138–142(MMHFG) of showed pH-dependent reactivity. They showed high signals towards PrP(90–231) modified below pH 4.7, and the signals fall down remarkably towards PrP(90–231) modified over pH 5.2, suggesting that these regions of PrP(90–231) were sensitive to pH shifts; however, the signals from the same region of the full length of PrP(29–231) showed no sensitivity to the entire pH shifts. This pH dependence of PrP(90–231) suggests the titration of an acidic region that might inhibit the N-terminal epitopes. A similar pH dependence for a monoclonal antibody reactive to the central region of 146–154(EDRYYRENM) identified an acidic region incorporating Glu152 as a significant participant (Figure 3) [12].

206520.fig.003
Figure 3: Affinity of moAbs to pH-modified PrP(23–231) and PrP(90–231) [12]. The pH dependence of the affinity of rFab 13A5 (fuchsia square), mAb 6H4 (green diamond), and mAb MAI–750 (yellow triangle) toward (a) SHaPrP(29–231) and (b) SHaPrP(90–231) after incubation at various pH values within the range 3.0–7.2 was tested. Four acidic residues are clustered in the central region within the nine residues 144–152, and rFab 13A5, mAb 6H4, and mAb MAI–750 could bind in this region. None of these antibodies showed any pH dependence of reactivity toward PrP(29–231), whereas MAI-750 showed a pH dependence around at pH 4 to 5 in its reactivity toward PrP(90–231). A further reduction in the reactivity of MAI-750 at very low pH suggests that the antibody is unable to bind to its epitope when the acidic groups are strongly protonated.
2.2. Temperature within Physiological Limits

Temperature-induced transition of Aβ40 plays an important role in the structural transformation from α-helix and random coil to β-sheet form in aqueous solution by heating [32]. High temperature induces structural changes in Aβ (tangle and plaques) or changes in brain similar to those observed in AD [33]. The conformation of Aβ40 at 0–20°C was α-helical, whereas conformational changes of Aβ40 towards β-sheet conformation were observed at between 35–45, 60–65, and 80–85°C [13].

The occurrence of changes within specific temperature ranges may indicate thermal specificity or adoption by Aβ40 of various conformations at wide range of heating, due to increasing intermolecular β-sheet structures [34]. The temperature within the physiological limits also induced the changes to Aβ40, the apparent changes were observed at 36–38°C in the amino acid residues 9–14, and the changes in the amino acid residues 17–21 were observed at 36–40°C [13], and both sequences have been reported to be involved in pH-induced conformational transition of Aβ40 [11] (Figure 4). The observation within physiological limits may occur in vivo with high fever over 38°C in response to inflammatory disease, and thermal stress may affect Aβ40 in our brain.

206520.fig.004
Figure 4: Affinity of moAbs to thermal-modified Aβ40 [13]. Enzyme-linked immunosorbent assay (ELISA) measurements of antibody affinity towards temperature-modified Aβ40 were performed. The reactivity of four antibodies as mentioned in Figure 2 (4G8, 6F/3D, anti-1–7, anti-5–10) to samples of Aβ40 that had been exposed to temperatures over the range 36–42°C at 1°C interval and at 20°C as a control, was monitored by ELISA. Statistical comparisons were performed with unpaired -tests. The values are means ± SEM. Statistically significant differences versus 6F/3D were determined at each temperature ( ). For both anti-5–10 and 1–7 antibodies, the reactivity was constant through the whole temperature range from 35°C to 42°C, and no temperature-dependent difference was detected. The monoclonal antibody 6F/3D showed temperature-dependent reactivity, and the reactivity was bimodal, when the modified temperature was increased from 36 to 38°C and from 38 to 41°C. On the other hand, 4G8 showed temperature-dependent reactivity, when the temperature increased from 36 to 40°C. Thus, the 9–14 and 17–21 amino acid residues within Aβ40 peptide were sensitive to temperature changes.

Temperature-dependent secondary structure of Aβ40, Aβ42 and Aβ28 in the solid state was also studied by simultaneous Fourier transform infrared/differential scanning calorimetry (FT-IR/DSC) microspectroscopic system. Basically, Aβ28 is composed from major β-sheet and minor α-helix with little random coil, and Aβ40 consisted of major β-sheet, minor random coil, and little α-helix, but Aβ42 mainly consisted of the predominant β-sheet structure. Thus, the intact Aβs show a different secondary structures, and thermal treatment induces a similar β-sheet structure for Aβ40 at 45°C and for Aβ28 at 40°C; however, there was no transitional temperature for Aβ42 [35]. Actually, temperature at 45°C induced changes for Aβ40 by reducing the compositions from 37 to 20–24% for α-helical and random coil structures but increasing the components from 27 to 45% for intermolecular β-sheet structures [34]. The thermal-induced denaturation is an important factor in the structural transformation from α-helix/random coil to β-sheet in Aβs.

2.3. Metal Ions

The metal ions such as Zn2+, Cu2+ were implicated in AD progression [3638], and their interaction with Aβ in stimulating Aβ aggregation has been studied in vitro. The binding of metal ions induces Aβ conformation, initially rich in random coil structure to a β-sheet structure, favorable the partially folding intermediates. Under acidic pH, Cu2+, and Fe3+ induce drastic aggregation; however, under neutral or alkaline pH, they showed limited propensity to Aβ aggregation [3941]. Oligomerization of the Aβ peptides can be rapidly induced in the presence of Zn2+ ions under physiological conditions [4244], and, under both at alkaline and acidic pH, it could induce Aβ aggregation and form protease resistant aggregates [45]. It was suggested that Aβ possesses preferential Zn2+-binding sites in its N-terminal 1–16 and the metal ion interacts with His-6, -13, and -14 both at acidic and alkaline pH [4648]. Recent reports suggests that soluble Aβ oligomers rather than matured Aβ fibrills exhibit the major neurotoxicity and these histidine residues may be a target to decrease the cytotoxicity [49] and suggested that a Pt compounds and Ru2+ complex may react with Aβ28 [50].

Recent report suggest the mechanisms and structures of amyloid formation by Zn2+ binding. Though Zn2+ does not affect the β-sheet association around the C-terminal hydrophobic region, it shifts the relative aggregation major species. As a result, Zn2+ coordination promotes Aβ42 aggregation leading to less uniform structures and increasing Zn2+ concentration slows down the aggregation rate [51].

Though there are many reports to demonstrate the neurotoxic effects and their interference with a variety of cellular and metabolic process, the pathogenesis of Al3+ in AD is still under debate [52, 53]. A comparative study under alkaline pH showed that Zn2+ and Cu2+ ions were much less efficient than Al3+ ion in stimulating the spontaneous fibril formation of Aβs. The putative Al3+-chelating amino acid residues are present both in the hydrophilic segment (Aβ1–16) and in the hydrophobic core (Aβ20–35), suggesting that the Al3+-binding is less restricted than that for Zn2+ and Cu2+, which is confined to the N-terminal sequence [54].

3. Application of Temperature-Induced Aβ40 Conformational Changes for AD Diagnostics [14]

The earlier intervention is required in AD treatments, and the determination of clinical phase of AD in early stage is necessary. Up to date, there are no reports about useful markers of AD staging.

We exposed Aβ40 peptide to the thermal shifts and observed the reactivity pattern to moAbs with an enzyme-linked immunosorbent assay (ELISA) before and after the exposures. The signals from Aβ40 before thermal exposure fall down after the exposure, in which Aβ40 oligomerization is induced by thermal shifts.

The clinical phase of AD was determined with MMSE, and mild AD presents MMSE over 24 and severe AD presents MMSE below 9. We used the sera from patients diagnosed with mild AD and severe AD to detect the different reactivity pattern to specific antibodies targeting Aβ17–21(4G8 moAb). The reactivity patterns of sera to 4G8 at 36–42°C was determined by ELISA. The Aβ40 peptide as a control showed the reactivity pattern in a temperature-dependent manner, and the reactivity of sera from patients with severe AD was less than that of sera from patients with mild AD though the temperatures 36–41°C and the remarkable fall down at 41-42°C were shown in severe AD, however, with no difference at 42°C (Figure 5(a)). The severity of AD is associated with greater Aβ40 aggregation. We propose that the ratio of differences of signals with ELISA between 38°C and 40°C is useful to determine the severity of AD (Figure 5(b)). The present results may be of value in staging and following up of patients with AD.

fig5
Figure 5: Identification of response of temperature-modified serum of patients with Alzheimer’s disease [14]. According to the criteria of National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders, AD patients were enrolled, and the patients were classified into two groups of mild AD and severe AD with age match. MMSE score 1–9 was as severe AD and the score of 10–22 was as mild AD. Sera from two AD groups were tested for their reactivity against 4G8 with ELISA. (a) The absorbance in the severe AD was lower than that of the mild AD though the temperatures and the signals from mild AD were almost constant; however, the significant lower signal was observed in severe AD at 40°C ( ) and 41°C ( ). The signals from Aβ40 peptide as a control showed decrease as the temperature increase in a temperature-dependent manner. (b) The minimum/maximum optical density ratio of each patient’s serum was calculated and obtained the average of ratios for severe and mild AD. The ratio value for patients with severe AD ( ) was significantly ( ) lower than that for patients with mild AD ( ). The average min/max optical density value for the synthetic Aβ1–40 peptide, used as a control, was .

4. Conclusion

Acidic environment at around pH 5, a temperature between 38-39°C within physiological limits, and Cu2+ and Zn2+ ion at neutral pH could precede Aβ40 from monomer to oligomers. The sequence of QKLVFFA is responsible of the changes, and it is crucial of Aβ oligomerization, and the sequence may be useful as a biomarker of Aβ40 oligomers in AD serum. The differences of Aβ40 conformation in AD patients serum were demonstrated as the different sensitivity of Aβ40 in response to the thermal shift, and it was detected with the moAb which recognizes QKLVFFA, corresponding to amino acids 15–21 of Aβ40/42 by ELISA. We suggest here a new diagnostic approach for AD staging by monitoring the reactivity mode of the moAb to Aβ40 before and after exposure to the thermal shift.

References

  1. R. Katzman and T. Saitoh, “Advances in Alzheimer's disease,” FASEB Journal, vol. 5, no. 3, pp. 278–286, 1991. View at Scopus
  2. T. L. Spires-Jones, K. J. Kopeikina, R. M. Koffie, A. de Calignon, and B. T. Hyman, “Are tangles as toxic as they look?” Journal of Molecular Neuroscience, vol. 45, no. 3, pp. 438–444, 2011.
  3. J. Götz, A. Schild, F. Hoerndli, and L. Pennanen, “Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models,” International Journal of Developmental Neuroscience, vol. 22, no. 7, pp. 453–465, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. P. V. Arriagada, J. H. Growdon, E. T. Hedley-Whyte, and B. T. Hyman, “Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease,” Neurology, vol. 42, no. 3 I, pp. 631–639, 1992. View at Scopus
  6. Y. Fukutani, K. Kobayashi, I. Nakamura, K. Watanabe, K. Isaki, and N. J. Cairns, “Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease,” Neuroscience Letters, vol. 200, no. 1, pp. 57–60, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Aggleton, H. S. Blindt, and J. N. Rawlins, “Effects of amygdaloid and amygdaloid-hippocampal lesions on object recognition and spatial working memory in rats,” Behavioral Neuroscience, vol. 103, no. 5, pp. 962–974, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Cirrito, P. C. May, M. A. O'Dell et al., “In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life,” Journal of Neuroscience, vol. 23, no. 26, pp. 8844–8853, 2003. View at Scopus
  9. G. D. Silverberg, M. Mayo, T. Saul, E. Rubenstein, and D. McGuire, “Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis,” Lancet Neurology, vol. 2, no. 8, pp. 506–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Shibata, S. Yamada, S. R. Kumar et al., “Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1489–1499, 2000. View at Scopus
  11. Y. Matsunaga, N. Saito, A. Fujii et al., “A pH-dependent conformational transition of Aβ peptide and physicochemical properties of the conformers in the glial cell,” Biochemical Journal, vol. 361, no. 3, pp. 547–556, 2002. View at Publisher · View at Google Scholar
  12. Y. Matsunaga, D. Peretz, A. Williamson, et al., “Cryptic epitopes in N-terminally truncated prion protein are exposed in the full-length molecule: dependence of conformation on pH,” Proteins, vol. 44, no. 2, pp. 110–118, 2001.
  13. F. F. Hatip, M. Suenaga, T. Yamada, and Y. Matsunaga, “Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Aβ40, by the β-sheet breaker peptides 16-23 and 17-24,” British Journal of Pharmacology, vol. 158, no. 4, pp. 1165–1172, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. F. F. Bolukbasi Hatip, Y. Matsunaga, and T. Yamada, “Specific reactivity of mild/severe Alzheimer's disease patient's sera to antibody against Aβ1-40 epitope 17-21,” Acta Neurologica Scandinavica, vol. 117, no. 6, pp. 404–408, 2008. View at Publisher · View at Google Scholar · View at PubMed
  15. A. W. Bero, P. Yan, J. H. Roh et al., “Neuronal activity regulates the regional vulnerability to amyloid-β 2 deposition,” Nature Neuroscience, vol. 14, no. 6, pp. 750–756, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. J. A. Hardy and G. A. Higgins, “Alzheimer's disease: the amyloid cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185, 1992.
  17. C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide,” Nature Reviews Molecular Cell Biology, vol. 8, no. 2, pp. 101–112, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Zhang, M. P. Lambert, C. Bunch et al., “Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer's Aβ peptide,” Journal of Biological Chemistry, vol. 269, no. 41, pp. 25247–25250, 1994.
  19. J. Busciglio, A. Lorenzo, J. Yeh, and B. A. Yankner, “β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding,” Neuron, vol. 14, no. 4, pp. 879–888, 1995.
  20. Y. Matsunaga, A. Fujii, A. Awasthi, J. Yokotani, T. Takakura, and T. Yamada, “Eight-residue Aβ peptides inhibit the aggregation and enzymatic activity of Aβ42,” Regulatory Peptides, vol. 120, no. 1–3, pp. 227–236, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. A. Itkin, V. Dupres, Y. F. Dufrêne, B. Bechinger, J.-M. Ruysschaert, and V. Raussens, “Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease,” PLoS ONE, vol. 6, no. 3, article e18250, 2011. View at Publisher · View at Google Scholar · View at PubMed
  22. B. J. Snider, A. M. Fagan, C. Roe et al., “Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type,” Archives of Neurology, vol. 66, no. 5, pp. 638–645, 2009. View at Publisher · View at Google Scholar · View at PubMed
  23. J. L. Cummings, “Biomarkers in Alzheimer's disease drug development,” Alzheimer's and Dementia, vol. 7, no. 3, pp. e13–e44, 2011. View at Publisher · View at Google Scholar · View at PubMed
  24. J. McLaurin, D. Yang, C. M. Yip, and P. E. Fraser, “Review: modulating factors in amyloid-β fibril formation,” Journal of Structural Biology, vol. 130, no. 2-3, pp. 259–270, 2000. View at Publisher · View at Google Scholar · View at PubMed
  25. D. R. Booth, M. Sunde, V. Bellotti et al., “Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis,” Nature, vol. 385, no. 6619, pp. 787–793, 1997. View at Publisher · View at Google Scholar · View at PubMed
  26. Y. Matsunaga, E. Ierovnik, T. Yamada, and V. Turk, “Conformational changes preceding amyloid-fibril formation of amyloid-beta and stefin B; parallels in pH dependence,” Current Medicinal Chemistry, vol. 9, no. 19, pp. 1717–1724, 2002.
  27. E. Turk, D. B. Teplow, L. E. Hood, and S. B. Prusiner, “Purification and properties of the cellular and scrapie hamster prion proteins,” European Journal of Biochemistry, vol. 176, no. 1, pp. 21–30, 1988.
  28. B. W. Caughey, A. Dong, K. S. Bhat, D. Ernst, S. F. Hayes, and W. S. Caughey, “Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy,” Biochemistry, vol. 30, no. 31, pp. 7672–7680, 1991.
  29. A. Taraboulos, A. J. Raeber, D. R. Borchelt, D. Serban, and S. B. Prusiner, “Synthesis and trafficking of prion proteins in cultured cells,” Molecular Biology of the Cell, vol. 3, no. 8, pp. 851–863, 1992.
  30. S. B. Prusiner, M. P. McKinley, K. A. Bowman, et al., “A protease-resistant protein is a structural component of the scrapie prion,” Cell, vol. 35, no. 1, pp. 57–62, 1983.
  31. M. Fischer, T. Rulicke, A. Raeber et al., “Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie,” EMBO Journal, vol. 15, no. 6, pp. 1255–1264, 1996.
  32. P. Sengupta, K. Garai, B. Sahoo, Y. Shi, D. J. Callaway, and S. Maiti, “The amyloid β peptide (Aβ1-40) is thermodynamically soluble at physiological concentrations,” Biochemistry, vol. 42, no. 35, pp. 10506–10513, 2003. View at Publisher · View at Google Scholar · View at PubMed
  33. R. Sinigaglia-Coimbra, E. A. Cavalheiro, and C. G. Coimbra, “Postischemic hyperthermia induces Alzheimer-like pathology in the rat brain,” Acta Neuropathologica, vol. 103, no. 5, pp. 444–452, 2002. View at Publisher · View at Google Scholar · View at PubMed
  34. H. L. Chu and S. Y. Lin, “Temperature-induced conformational changes in amyloid β(1-40) peptide investigated by simultaneous FT-IR microspectroscopy with thermal system,” Biophysical Chemistry, vol. 89, no. 2-3, pp. 173–180, 2001. View at Publisher · View at Google Scholar
  35. S.-Y. Lin, H.-L. Chu, and Y.-S. Wei, “Secondary conformations and temperature effect on structural transformation of amyloid β (1-28), (1-40) and (1-42) peptides,” Journal of Biomolecular Structure and Dynamics, vol. 20, no. 4, pp. 595–601, 2003.
  36. P. Faller and C. Hureau, “Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide,” Dalton Transactions, vol. 21, no. 7, pp. 1080–1094, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. D. Drago, S. Bolognin, and P. Zatta, “Role of metal ions in the Aβ oligomerization in Alzheimer's disease and in other neurological disorders,” Current Alzheimer Research, vol. 5, no. 6, pp. 500–507, 2008. View at Publisher · View at Google Scholar
  38. E. Gaggelli, H. Kozlowski, D. Valensin, and G. Valensin, “Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis),” Chemical Reviews, vol. 106, no. 6, pp. 1995–2044, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. P. W. Mantyh, J. R. Ghilardi, S. Rogers et al., “Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide,” Journal of Neurochemistry, vol. 61, no. 3, pp. 1171–1174, 1993.
  40. C. S. Atwood, R. D. Moir, X. Huang et al., “Dramatic aggregation of alzheimer by Cu(II) is induced by conditions representing physiological acidosis,” Journal of Biological Chemistry, vol. 273, no. 21, pp. 12817–12826, 1998. View at Publisher · View at Google Scholar
  41. E. House, J. Collingwood, A. Khan, O. Korchazkina, G. Berthon, and C. Exley, “Aluminium, iron, zinc and copper Influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 6, no. 3, pp. 291–301, 2004.
  42. A. I. Bush, W. H. Pettingell, G. Multhaup et al., “Rapid induction of Alzheimer Aβ amyloid formation by zinc,” Science, vol. 265, no. 5177, pp. 1464–1467, 1994.
  43. K. H. Lim, Y. K. Kim, and Y. T. Chang, “Investigations of the molecular mechanism of metal-induced Aβ (1-40) amyloidogenesis,” Biochemistry, vol. 46, no. 47, pp. 13523–13532, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. E. F. Ali, F. Separovic, C. J. Barrow, S. G. Yao, and K. J. Barnham, “Copper and zinc mediated oligomerisation of Aβ peptides,” International Journal of Peptide Research and Therapeutics, vol. 12, no. 2, pp. 153–164, 2006. View at Publisher · View at Google Scholar
  45. A. I. Bush, “The metallobiology of Alzheimer's disease,” Trends in Neurosciences, vol. 26, no. 4, pp. 207–214, 2003. View at Publisher · View at Google Scholar
  46. J. Dong, C. S. Atwood, V. E. Anderson et al., “Metal binding and oxidation of amyloid-β within isolated senile plaque cores: raman microscopic evidence,” Biochemistry, vol. 42, no. 10, pp. 2768–2773, 2003. View at Publisher · View at Google Scholar · View at PubMed
  47. T. Miura, K. Suzuki, N. Kohata, and H. Takeuchi, “Metal binding modes of Alzheimer's amyloid β-peptide in insoluble aggregates and soluble complexes,” Biochemistry, vol. 39, no. 23, pp. 7024–7031, 2000. View at Publisher · View at Google Scholar
  48. S. T. Liu, G. Howlett, and C. J. Barrow, “Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer's disease,” Biochemistry, vol. 38, no. 29, pp. 9373–9378, 1999. View at Publisher · View at Google Scholar · View at PubMed
  49. N. Arispe, J. C. Diaz, and M. Flora, “Efficiency of histidine-associating compounds for blocking the Alzheimer's Aβ channel activity and cytotoxicity,” Biophysical Journal, vol. 95, no. 10, pp. 4879–4889, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. D. Valensin, P. Anzini, E. Gaggelli et al., “Fac-{Ru(Co)3}2+ selectively targets the histidine residues of the β-amyloid peptide 1–28. Implications for new Alzheimer’s disease treatments based on ruthenium complexes,” Inorganic Chemistry, vol. 49, no. 11, pp. 4720–4722, 2010. View at Publisher · View at Google Scholar · View at PubMed
  51. Y. Miller, B. Ma, and R. Nussinov, “Zinc ions promote alzheimer aβ aggregation via population shift of polymorphic states,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 21, pp. 9490–9495, 2010. View at Publisher · View at Google Scholar · View at PubMed
  52. V. B. Gupta, S. Anitha, M. L. Hegde et al., “Aluminium in Alzheimer's disease: are we still at a crossroad?” Cellular and Molecular Life Sciences, vol. 62, no. 2, pp. 143–158, 2005. View at Publisher · View at Google Scholar · View at PubMed
  53. P. Zatta, M. Favarato, and M. Nicolini, “Deposition of aluminium in brain tissues of rats exposed to inhalational of aluminium acetylacetonate,” NeuroReport, vol. 4, no. 9, pp. 1119–1122, 1993.
  54. F. Ricchelli, D. Drago, B. Filippi, G. Tognon, and P. Zatta, “Aluminum-triggered structural modifications and aggregation of β-amyloids,” Cellular and Molecular Life Sciences, vol. 62, no. 15, pp. 1724–1733, 2005. View at Publisher · View at Google Scholar · View at PubMed